Promomed Group summed up the results of SPIEF 2022

Eight presentations at the forum events – sessions and discussions on the pharmaceutical industry, regulation and measures to support innovation; five new agreements on cooperation and development of promising projects; meetings with heads of regions and government representatives; negotiations with partners and investors, as well as numerous interviews and comments – these are the results for Promomed Group 25- The 20th anniversary SPIEF 2022, which became the first for the company.

The forum was attended by Peter the White, Chairman of the Board of Directors of Promomed Group, Dmitry Zemskov, Executive Director of JSC Biochemist (part of the Promomed Group) and Kira Zaslavskaya, Director of New Products at Promomed Group.

Promomed Group of Companies signed an agreement on the sidelines of the St. Petersburg International Economic Forum with The Skolkovo Foundation¹ in order to start joint work in the field of developing biotechnological drugs, new dosage forms, improving methods of synthesizing pharmaceutical substances, conducting preclinical and clinical studies, and creating a modern research center. And also with the largest universities²: Russian University of Chemical Technology named after Mendeleev, Moscow State Medical and Dental University named after Evdokimov, National Research University of Mordovia named after Ogarev and St. Petersburg State Chemical and Pharmaceutical University in order to develop professions related to high-tech production in the field of pharmacy, train highly specialized specialists, improve the skills of pharmaceutical production workers and conduct joint research in the field of new drug development.

As part of the launch day "Drug safety»³ Dmitry Zemskov Speaking at the first plenary session, he called for preserving the experience gained during the pandemic and preserving previously established industry support mechanisms, especially for new original drugs, as the most important catalyst for the development of the industry. The speaker noted that the industry is currently facing certain limitations in auxiliary substances and analytical equipment. "All the difficulties are being successfully solved, however, it is important to put the production of technologies and compounds on stream," he stressed. Kira Zaslavskaya I noticed, that one of the most important steps that the domestic pharmaceutical industry can take to develop the innovation market is cooperation with research centers: "In order to quickly create innovative drugs, you need to constantly be in the same information field with research institutes, create platforms for inventory and discussion of R&D."

In the track "Healthy Society"⁴ atPrivate traders outlined innovative solutions and strategies that will allow Russian pharmaceutical and medical companies to take the lead in the new economic conditions. Peter the White Assessing the current increased responsibility of the domestic pharmaceutical industry, he stressed the need to refrain from pursuing import substitution: "It is not necessary to turn the domestic market into a country of generics. It is necessary to focus on unique promising developments in cooperation with the government and scientific centers." Dmitry Zemskov, answering the question about the right to call an innovative plant with a 60-year history, he spoke about a broad modernization program with the expansion of production, stressing that today the Biochemist – the newest factory with a rich history.

The theme of the final day was "Investing in health: effective cooperation between business and society»⁵. Within the framework of the dialogue that took place Peter the White He said: "We need to think about how to make Russia a country that produces a large number of next-in-class drugs.⁶ or first-in-class⁷. This is a crucial issue. Yes, it is much more difficult to make first-in-class drugs, but it is necessary that their production in the main therapeutic groups become a national policy." "And for enterprises engaged in innovative activities, for example, developing Russian pharma, producing domestic drugs, it is necessary to provide benefits and expand the dialogue with them," he continued. Dmitry Zemskov"tax preferences and business assistance should apply not only to residents of special economic zones."

¹ Promomed Group begins joint work with Skolkovo Foundation
² Leading universities of the country will train specialists for Promomed Group of Companies
³ Promomed Group of Companies at the SPIEF. Day One: "Drug Safety"
^4,5 Promomed Group of Companies at the SPIEF. Day two: "The course for innovation"
⁶ "Next-in-class" drugs are original medicines protected by a patent, possessing similar therapeutic properties and mechanisms of action, resembling already successfully used medicines.
⁷ "First-in-class" drugs are "first in their class", innovative new drugs that have not yet been on the market, acting on a fundamentally new target.